Please login to the form below

Not currently logged in

RedHill Biopharma’s SK2 inhibitor shows promise against coronavirus

Opaganib demonstrate potent inhibition of SARS-CoV-2 in an in vitro test

RedHill Biopharma has announced that its experimental sphingosine kinase-2 (SK2) opaganib demonstrated potent inhibition of SARS-CoV-2 in an in vitro clinical test.

According to the company, the potential first-in-class treatment was able to achieve complete blockage of viral replication in an in vitro model of human lung bronchial tissues.

Opaganib possesses both anti-inflammatory and anti-viral activity, by targeting a host cell component unaffected by viral mutation, which minimises the likelihood of resistance.

RedHill is currently evaluating the SK2 inhibitor in global phase 2/3 and US phase 2 clinical studies for the treatment of severe COVID-19-associated pneumonia.

According to the company, opaganib demonstrated the most potent activity against SARS-CoV-2 compared to all compounds tested in the same study, including the positive control, Gilead’s remdesivir.

“Opaganib’s previously demonstrated anti-inflammatory activity, combined with our now proven specific anti-SARS-CoV-2 viral activity, provides a unique dual mechanism of action with the potential to greatly benefit COVID-19 patients by inhibiting the key drivers of disease progression - viral replication and lung inflammation,” said Mark Levitt, medical director at RedHill.

“This compelling data, using a physiologically relevant human respiratory tissue model, demonstrates opaganib’s potential to strongly inhibit SARS-CoV-2 viral replication, validating the hypotheses underlying our ongoing global phase 2/3 and US phase 2 clinical studies and further supporting their rationale,” he added.

Article by
Lucy Parsons

9th September 2020

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company Events and Exhibition Stands is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...